Skip to content

CASCADE analysis finds antiretroviral treatment benefits are evident below CD4 count of 500, uncertain above this level

Prevention strategies need to target both early and chronic HIV infection

Neurocognitive impairment linked to prior low CD4 cell count, even if on current suppressive HIV treatment

Good results seen with NRTI-sparing regimens of atazanavir plus newer drug classes

Mass testing campaign unjustified if people fail to receive treatment, activist argues

'The business of public health': new research on financing of HIV programmes

Evidence-based treatment of drug users needed to strengthen human rights, stem drug use, and halt the HIV epidemic

New studies strengthen evidence that drug addiction is a disease of the brain; substitution therapy necessary

Less than 10% of East European prevention spending is for vulnerable groups

International AIDS Conference, Vienna 2010: Maternal and child health issues

HIV & TB in Practice

Loss to follow-up: health system, not patients, to blame

Three tactics to stem the tide of criminal prosecutions

Outcomes still improving for HIV patients in the UK

Increased mortality risk for treatment-naive patients with CD4 count below 500

Lymphocyte count and haemoglobin can predict prognosis of patients starting ART

Symptoms can predict increases in viral load for patients taking HIV treatment